Omni Bio Pharmaceutical’s recombinant Fc-AAT development program is progressing through preclinical work in preparation for conducting clinical trials in 2014
Novel discoveries over the past 10 years indicate that AAT has the potential to address a variety of indications including diabetes, transplant rejection, radioprotection, bacterial and viral diseases, myocardial remodeling and inflammatory bowel disease.
Omni Bio Pharmaceutical, Inc. (OTC: OMBP) is an emerging biopharmaceutical company that was founded on a monetization strategy for licensing issued and pending patents for new uses of an existing FDA-approved drug, alpha-1 antitrypsin (AAT). We have been funding sponsored research, supporting clinical trials and collaborating with existing AAT manufacturers to further these efforts.
More recently, we have advanced our strategy to create a patent-protected pipeline of recombinant Fc fusion molecules of alpha-1 antitrypsin (Fc-AATs) that are targeted for the treatment of a variety of serious immunological diseases, including Type 1 diabetes, bone marrow transplantation rejection (graft vs host disease), treatment-refractory gout, and inflammatory bowel disease.
Learn more about alpha-1 antitrypsin (AAT)
June 3, 2013 VIEW Report
April 11, 2013 VIEW Report
March 15, 2013 VIEW Press Release
February 6, 2013 VIEW Press Release
Watch this video to learn more about Omni Bio's breakthrough research for plasma and synthetic Alpha-1 Antitrypsin (AAT).
Dr. Charles Dinarello discusses article he co-authored in Blood Magazine
OmniBio proudly follows these fine groups and organizations
